Trials / Recruiting
RecruitingNCT06863233
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zirconium Zr 89 crefmirlimab berdoxam | Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89. |
| DIAGNOSTIC_TEST | PET/CT Scan | Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours). |
Timeline
- Start date
- 2025-03-03
- Primary completion
- 2028-03-03
- Completion
- 2028-03-03
- First posted
- 2025-03-07
- Last updated
- 2025-08-12
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06863233. Inclusion in this directory is not an endorsement.